Aytu BioPharma, Inc. develops and commercializes prescription medicines focused on complex central nervous system diseases. Its recurring company updates center on EXXUA (gepirone) extended-release tablets, an FDA-approved selective serotonin 5HT1a receptor agonist for major depressive disorder in adults, along with its ADHD products and legacy pediatric portfolio.
News from Aytu also covers operational and financial results, commercial launch activity, retail and Aytu RxConnect patient-access distribution, investor presentations, and product-level clinical and safety information for EXXUA. The company is a Nasdaq-listed specialty pharmaceutical issuer with prescription products sold through commercial distribution channels.
Aytu BioScience announced promising results from a pilot study using its Healight technology on mechanically ventilated COVID-19 patients. The study showed that endotracheal ultraviolet A (UVA) light therapy significantly reduced SARS-CoV-2 viral load by over 99% and improved clinical severity scores. Conducted on five patients, the treatment was well tolerated with no serious adverse effects reported. Aytu plans to further collaborate with the FDA and explore additional applications beyond COVID-19.
Aytu BioScience (NASDAQ:AYTU) has announced that CEO Josh Disbrow will present at three investor conferences in March 2021. The events include:
- Cowen 41st Annual Healthcare Conference: March 3, 2021, at 10:20 a.m. ET.
- H.C. Wainwright Global Life Sciences Conference: Pre-recorded chat available March 9, 2021, at 7:00 a.m. ET.
- Oppenheimer 31st Annual Healthcare Conference: March 16, 2021, at 4:30 p.m. ET.
These presentations can be accessed on the Aytu website.
Aytu BioScience announced a definitive merger with Neos Therapeutics, creating a combined specialty pharmaceutical entity with projected revenues of $100 million. For Q2 2021, Aytu reported net revenues of $15.1 million, a significant increase from $13.5 million in Q1 2021, with the Consumer Health division achieving an all-time revenue high of $7.9 million. The Rx division revenue rose 24% sequentially to $7.2 million. Despite a net loss of $9.5 million, Aytu maintains a strong cash position of $62.3 million, indicating financial stability as they approach the merger's closing in Q2 2021.
Aytu BioScience (NASDAQ:AYTU) and Neos Therapeutics (NASDAQ:NEOS) have scheduled special stockholder meetings for March 18, 2021, to discuss their proposed merger. The record date for eligibility to vote is February 5, 2021. Upon closing, the new entity will be rebranded as Aytu Biopharma, Inc., and will retain the AYTU ticker symbol on Nasdaq. Both companies’ Boards recommend stockholders vote 'FOR' the merger proposals. The joint proxy statement/prospectus will be mailed on February 12, 2021, providing further details on the merger process.
Aytu BioScience, Inc. (NASDAQ:AYTU) announced a conference call to discuss its operational results for the fiscal second quarter ending December 31, 2020, scheduled for February 11, 2021, at 4:30 PM ET. During this call, the company will highlight its quarterly accomplishments and future business strategies. Aytu markets several FDA-approved products, including Natesto, ZolpiMist, and Tuzistra XR, along with a range of pediatric medications. Additionally, Aytu is actively involved in COVID-19 testing and has licensed Healight™ technology for potential respiratory treatments.
Aytu BioScience, a specialty pharmaceutical company, announced the completion of a safety study for its Healight™ ultraviolet A light catheter technology. This study focused on critically ill COVID-19 patients on mechanical ventilation in the U.S. The safety data will be presented to the FDA for potential treatment of SARS-CoV-2. CEO Josh Disbrow highlighted this as a significant milestone, aiming for continued FDA discussions. This technology is designed to reduce viral and bacterial loads, with promising pre-clinical findings paving the way for human trials.
Aytu BioScience, a specialty pharmaceutical company, announced its presentation at the LD Micro Virtual Investor Conference on December 15, 2020, at 2:20 PM ET. This conference features a new format, allowing each company a 10-minute presentation followed by a 10-minute Q&A session with investors and analysts. Aytu's portfolio includes unique FDA-approved products addressing significant patient needs in primary care and pediatrics. For more details, visit the webcast.
Aytu BioScience (NASDAQ:AYTU) announced an underwriting agreement with H.C. Wainwright & Co. for a public offering of 1,666,667 shares at $6.00 per share. Expected gross proceeds are approximately $10 million, aimed at working capital and corporate purposes. Furthermore, the underwriter has a 30-day option to purchase an additional 250,000 shares. This offering follows the company's previously filed registration statement and is subject to customary closing conditions.
Aytu BioScience (NASDAQ:AYTU) will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference on November 18, 2020, at 1:45 PM ET / 6:45 PM GMT. The presentation will highlight the company's focus on novel pharmaceutical products, including FDA-approved treatments for low testosterone and sleep aids. A webcast of the presentation will be available online. Aytu's portfolio includes various prescription and consumer healthcare products aimed at significant patient needs, along with COVID-19 testing solutions.
Aytu BioScience (NASDAQ:AYTU) will announce its operational results for Q1 FY2021, ending September 30, 2020, on November 12, 2020, at 4:30 PM ET. The conference call will address the company’s recent achievements and future strategies. Aytu’s portfolio includes unique FDA-approved products like Natesto, ZolpiMist, and Tuzistra XR. Additionally, the company has a rapid COVID-19 testing solution and has licensed the Healight technology for respiratory infections. A live webcast will be available for 90 days on their website.